Business Plan for POC Diganostic Device for applications in Geriatrics and Clinical Trials.

1. Business Plan
CANASITA
Enabling Bioscience Processors

2. USA IVD Market Opportunity: $35 Billion
Source: Yole Development Market Research Report (Sep, 2012)
USA Elderly Population:
 40 Million aged 65 or older
 88 Million aged 65 or older by 2050
USA Affordable Care Act (2014):
 30 Million newly covered patients
$900 Million (2017)

3. A. Geriatrics Care: Nursing Homes & Assisted Living
B. POC Diagnostics: State of Health Panel Test
Pain Point:
 Delayed Prognosis:
Slow turnaround time (12/24hrs) from Blood Samples to Results
 Cost & Inconvenience:
Multiple Visits to Doctors, Specialists & Labs.
Laboratory Specialists, Complex Equipment & High CapEx.
POC Opportunity in Healthcare

4. Cytochrome (CYP) P450 Biosensor:
 CYP enzymes and transporters, have profound effects on the activity and
expression and therefore also the final biological activity, efficacy and safety of
drugs.
 90% of marketed drugs are metabolized by only five CYP isoforms (CYP1A2,
CYP2C9, CYP2C19, CYP2D6, CYP3A4/5)
Pain Point:
 Cost & Time: Currently-available methods (GC, HPLC, MS) used for in vitro
quantifying the levels of drugs in biological fluids are time-consuming, require
complex instruments and expensive ($300/patient).
 Limitations: Cannot measure plasma concentrations of drugs or their metabolites
during pharmacological cure. Ex: Transplant Patients
POC Opportunity: Clinical Trials & Drug Monitoring

5.  Simple & Elegant POC Solution.
 Fully Integrated Microfluidic Processor Platform
 Nano-Particle Based Cell Detection & Quantification
 Low-Cost Point-of-Care Diagnostic Instrument
 CLIA Waiver.
Canasita Solution

6. Canasita: Revenue & Business Plan
Note:
1. Assumes Tax Rate of 35%
2. COGS include licensing and royalty payments where applicable
3. R&D Costs include cost of Clinical Trials where applicable

7. 5-Year Goals:
 Year-2/Year-3: Solution for Clinical Trials Market
 Year-3/Year-4: Solution for Blood Analysis Market
 Year-4/Year-5: Solution for Urine Analysis Market
Market Share Goals (FY-2017):
 3% - 5% : Urine Analysis Market.
 3% - 5% : Blood Analysis Market
 5%: Clinical Trials Market
Financial Targets (FY-2017):
 COGS: 45%
 R&D: 20%
 SG&A: 15%
5-Year Goals and Objectives